PureTech to Present Phase 1b LYT-200 Results at ESMO 2026
PureTech announced that results from the completed Phase 1b trial of LYT-200 in relapsed/refractory high-risk myelodysplastic syndromes and acute myeloid leukemia will be presented at ESMO 2026.
Story updates
06:00:56 AM UTC
SquawkNews
PureTech Health will present completed Phase 1b results for LYT-200 in R/R HR-MDS and AML at ESMO 2026 on Oct. 24 in Madrid, and says the data support advancing to Phase 2.Material DetailsContext by AI AnalystThis fits PureTech’s strategy of advancing founded entities’ assets; LYT-200 moves from ea…